News

Gilead will now initiate two new clinical trials, for both treatment-naïve and multidrug resistant HIV-1.

The committee initially published a draft final appraisal for the drug in October, and just last week the SMC approved the treatment for use on NHS Scotland.

Patients had 50% fewer flares on the drug compared to placebo.

The money will go towards a potential new therapy and project, seeking to discover new ways that may prevent brain cell death.

24-week data from the clinical trial showed at least a 20% improvement in disease signs and symptoms compared to placebo.

The committee accepted breast cancer and kidney cancer treatments, but rejected one non-small cell lung cancer (NSCLC) therapy.

The drug met its primary endpoint, demonstrating superiority compared to placebo with standard of care.

The results are from the largest placebo-controlled study ever undertaken in type I or III SMA patients.

The agreement is expected to be completed within 30-45 days.

Topline results showed that the drug didn’t meet the primary endpoints of superior overall survival, compared with standard of care.

Despite the good news, there is still “disappointment surrounding the restrictions on prescribing cannabis-based drugs in the UK.”

The data marks an important milestone for CKD-related anaemia patients, as it is the “first innovation of its kind for this market in many years.”

The treatment fell short of its primary endpoint of increase in ongoing pregnancy rate at 10 weeks.

Keytruda is predicted to be the best-selling drug by annual revenue in 2023.